Search Results

Azitra, Inc. today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares.

Azitra, Inc. today announced preclinical data from the Company’s platform and pipeline.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported financial results for the three months ended March 31, 2024, and provided a business update.

Azitra, Inc. today reported financial results for the full year ended December 31, 2023, and provided a business update.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced preclinical data from the Company’s platform and pipeline.

Azitra, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. patent No. 11,850,267 covering future potential pipeline candidates for indications including ichthyosis vulgaris, titled “Methods and compositions for treating skin disease with recombinant microorganisms.” Travis Whitfill, Azitra’s COO, co-founder, and inventor of the patent stated, “Securing this patent is crucial for expanding our pipeline.

Azitra, Inc. announced that management will present at the ThinkEquity Conference in New York City on October 19 at 3:00pm ET.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced preclinical data from the Company’s platform and pipeline.